Adaptin BIO, Inc. (APTN) intrinsic value & 10-year financials
Adaptin BIO, Inc. (APTN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 263.8%
- Free cash flow (FY2025)
- —
APTN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$5.2M | -$0.66 | — | — | 586.1% |
| FY2024 | — | -$161.2K | -$0.03 | — | — | 83.3% |
| FY2023 | — | -$85.6K | -$0.02 | — | — | 122.1% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ADAPTIN BIO, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ADAPTIN BIO, INC. has earned high returns on invested capital, averaging 70.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
ADAPTIN BIO, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ADAPTIN BIO, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.